Low pass whole methylome enzymatic sequencing of four AML cell lines untreated and after treatment with different concentrations of 5-azacytidine (AZA), 5-aza-2'-deoxycytidine (DEC), Cytarabine (ARAC) and GSK3685032 (GSK5032) for 3 and 7 days

We conducted low-coverage whole-genome enzymatic methylation sequencing (EM-seq) on four commercially available AML cell lines to assess their global DNA methylation profiles following treatment with varying concentrations (0–3000 nM) of three different hypomethylating agents—5-azacytidine (AZA), 5-aza-2'-deoxycytidine (DEC), and GSK3685032 (GSK5032)—for 3 and 7 days (only GSK5032), as well as Cytarabine (ARAC) for 3 days.